SCHEMBL10316161

SCHEMBL10316161

CCc1c(C(=O)NCC2CCCO2)n(C)c2cc(CC)n(CC(=O)c3ccccc3)c(=O)c12

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.51
▸ HPGD P15428 5/20 0.48
▸ SMO Q99835 1/20 0.48
▸ KDM4E B2RXH2 3/20 0.47
▸ SMN1; SMN2 Q16637 3/20 0.47
▸ HSD17B10 Q99714 3/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ HTT P42858 1/20 0.47
▸ RAB9A P51151 3/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ NPC1 O15118 1/20 0.45
▸ LMNA P02545 1/20 0.45
▸ GAA P10253 1/20 0.45
▸ TSHR P16473 2/20 0.44
▸ TP53 P04637 1/20 0.44
▸ ATM Q13315 2/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ MAPK1 P28482 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10316157 0.82 SMO (0.50) HPGDSMOKDM4EHSD17B10ALDH1A1
SCHEMBL12826288 0.81 SMO (0.51) SMOALDH1A1RAB9ANPC1
SCHEMBL10316145 0.81 SMO (0.47) SMOALDH1A1RAB9ANPC1LMNA
SCHEMBL1057397 0.81 POLB (0.50) POLBHPGDSMOKDM4ESMN1; SMN2
SCHEMBL10316154 0.81 SMO (0.60) SMOKDM4EALDH1A1
SCHEMBL11976393 0.81 SMO (0.60) SMOKDM4EALDH1A1
SCHEMBL10316158 0.80 SMO (0.52) SMOALDH1A1GAATSHR
SCHEMBL11976396 0.80 SMO (0.52) SMOALDH1A1GAATSHR
SCHEMBL10316159 0.80 SMO (0.52) SMOALDH1A1GAATSHR
SCHEMBL10316166 0.80 SMO (0.48) SMOKDM4EALDH1A1LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8927718-B2 Fused heterocyclic ring derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-01-06 — — US disclosed
US-8927718-B2 Fused heterocyclic ring derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-01-06 — — US disclosed
US-20120208794-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-16 — — US disclosed
US-20120208794-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-16 — — US disclosed
EP-2471791-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed
WO-2011024873-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF 武田薬品工業株式会社 (JP) 2011-03-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208794-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH POLB 4723/4885HPGD 539/4885SMO 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback